BioCentury
ARTICLE | Financial News

Fibrotic disease company Pliant raises $62M series B

July 20, 2018 4:35 PM UTC

Fibrosis play Pliant Therapeutics Inc. (Redwood City, Calif.) raised $62 million on July 16 in an untranched series B round led by Cowen Healthcare Investments. Fellow new investors Eventide Asset Management, Schroder Adveq, Menlo Ventures, SCubed Capital, Agent Capital and undisclosed institutional investors also participated.

Third Rock Ventures launched Pliant in 2016 to develop selective integrin inhibitors that enable the company to block transforming growth factor (TGF) beta in the fibrotic process without affecting healthy tissues (see "Fibrosis Frontal Attack")...